Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
|Live BSE Quotes||Oct 25, 2016 (Close)|
|Price (Rs)824.25||Open (Rs) 817.60||High (Rs) 831.00||Low (Rs) 817.60|
|% Change0.78||Volume 204,602||Value (Rs) 168,790,411||52-Week H/L 895.00 / 582.00|
|Live NSE Quotes||Oct 25, 2016 (Close)|
|Price (Rs)824.90||Open (Rs) 819.50||High (Rs) 831.25||Low (Rs) 819.00|
|% Change0.79||Volume 1,027,160||Value (Rs) 847,771,857||52-Week H/L 895.00 / 582.00|
|EPS (Rs)* 37.19||P/E Ratio (x) 22.16||Market Cap (Rs m) 480,471.81||P/BV (x) 6.81|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|AUROBINDO PHARMA Stock Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.
Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.
Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.More Views on News
A brief discussion on one BHK apartments going for Rs 1.8 crore in Mumbai and why it makes no sense.
Are we really on our way to becoming the 'India of our dreams'?
Apurva talks about his Secret Profit Signal and his first ever training session
Why the PE ratios of mid caps and small caps are currently at such lofty levels.
PersonalFN explains why top performing mutual fund schemes may not always be the perfect fit for your investment portfolio.More